KOL Conversation on IBD

Join Dr. Russell Cohen, Professor of Medicine and Clinical Director of the IBD Center at the University of Chicago, and Dr. Parambir Dulai, Director of Precision Medicine at Northwestern University, for an in-depth discussion recorded live at the GI ReConnect Conference in Denver. In this expert-led podcast, the faculty review the evolving therapeutic landscape in inflammatory bowel disease (IBD), including novel and emerging drug classes such as IL-23 inhibitors, S1P modulators, JAK and TYK2 inhibitors, and anti-TL1A agents. Dr. Dulai outlines current strategies for combination therapy, highlights the challenges of therapeutic durability, and emphasizes the potential for small molecules to transform episodic management. The conversation explores precision medicine, the role of biomarkers, microbiome-targeted approaches, metabolic comorbidities, and cardiovascular risks in IBD. The faculty also touch on extraintestinal manifestations like arthritis and pyoderma gangrenosum, weighing how these impact treatment selection. This session is a must-watch for clinicians interested in optimizing long-term outcomes in Crohn’s disease and ulcerative colitis through early intervention, tailored therapy, and sustained disease control. Presented by GIHF, this episode reflects cutting-edge thinking at the forefront of IBD care.